DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings - Video
|
Overview
DAa-ViNCI study which analyzed the efficacy, safety and practice of pattern of Vildagliptin 100mg and dapagliflozin 10mg in cardiology practice.
This study, conducted by eminent cardiologists Dr. J.C. Mohan, Dr. Mahesh K. Shah, and Smit Shrivastava, was published in the May 2025 issue of the European Society of Medicine, Medical Research Archives.
It is a first of its kind Indian study done on the role of Vildagliptin-Dapagliflozin FDC on CV risk T2D patients in Indian cardiology settings and the second study after REFORM, that has been supported by USV in the domain of this FDC.
This retrospective, non-randomized, multicenter study was conducted across 200 cardiology centers in India. It included 2,199 patients with type 2 diabetes of whom a substantial proportion had cardiovascular (CV) risks- 74.81% had hypertension, 38.52% had dyslipidemia, and 14.6% had CAD. The mean age was 55.04 years. All patients received vildagliptin 100mg SR and dapagliflozin 10mg FDC and patients were also on other concomitant medication for their comorbidities.
Some of the key highlights of the study are:
1) Significant Glycemic Improvement: Following early initiation, HbA1c levels significantly declined from 7.7% to 5.8%- a 1.9% reduction-bringing values close to normoglycemia within just 3 months.
2) Better Fasting & Postprandial Glucose: Fasting plasma glucose (FPG) dropped from 142.4 mg/dL to 90.2 mg/dL, reduction of 52.2 mg/dL, while postprandial glucose (PPG) declined from 205.6 mg/dL to 123.3 mg/dL, reduction of 82.3 mg/dL.
3) There was a notable reduction in blood pressure, with systolic BP a reduction of 10 mmHg and diastolic BP a reduction of 5 mmHg.
4) 78% of patients successfully achieved their glycemic targets.
Most physicians in the study found the vildagliptin-dapagliflozin combination to be effective and well-tolerated. 82% experts consider it a strong treatment option for T2DM due to its complementary mechanisms of action of DPP-4 inhibitors and SGLT2 inhibitors.
This study brings out a clinical message that early inclusion of Vildagliptin Dapagliflozin based combination therapy may help to achieve not only durable glycemic control but also improve intermediate CV risk markers in high-CV risk T2D patient population.
Speakers
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751